BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 17478466)

  • 1. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
    Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
    Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
    Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
    Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
    J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H; Okada AA; Watanabe T; Taki W
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azathioprine in severe uveitis of Behçet's disease.
    Saadoun D; Wechsler B; Terrada C; Hajage D; Le Thi Huong D; Resche-Rigon M; Cassoux N; Le Hoang P; Amoura Z; Bodaghi B; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1733-8. PubMed ID: 20665749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
    Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M
    Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
    Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
    Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
    Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
    Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.